From: p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
Gene | Source | Treatment | Case/control | Up/downa | Ref |
---|---|---|---|---|---|
MMP-12 | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [148] | |
IL-16 | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
IL-27 | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
Leptin | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
TCA-3 | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
KC (CXCL-1) | COPD model in Mice (BALF sample) | CS + LPS | CS + LPS/PBS | Up-P | [147] |
Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] | |
Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] | |
CRP | Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] |
Circulating chemokine (COPD GOLD II) | GW856553 | GW856553/Plasebo | Down-P | [149] | |
Human COPD (GOLD II/III) | PH-797804 | PH-797804/Placebo | Down-P | [55] | |
ITAC | Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] |
Adiponectin | Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] |
Prolactin | Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] |
uPAR | Emphysema mice model (BALF sample) | CS + LPS | Emphysema mice/WT | Up-P | [147] |
FAM-174A | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
ADM | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
CCL-8 | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
CXCL-1 | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
IL-1β | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] | |
TLR-1 | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
ZNF-519 | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
MMP-9 | Whole blood (Human COPD) | Dilmapimod | Dilmapimod/placebo | Down-G | [54] |
Guinea Pig BAL fluid | SB 239063 + LPS | SB 239063 + LPS/LPS | Down-P | [40] | |
COX-2 | CS exposed rat | MSC + CS | MSC + CS/CS | Down-P | [39] |
PGE-2 | CS exposed rat | MSC + CS | MSC + CS/CS | Down-P | [39] |
CXCL-8 | Septum (human COPD) | - | COPD/healthy | Up-G&P | [143] |
MMP-2 | Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] |
TNFα | Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] |
alveolar macrophages (COPD GOLD IV) | LPS + AZD7624 | COPD/healthy | Down-P | [144] | |
Rat whole blood | SB-239063 + LPS | SB 239063 + LPS/LPS | Down-P | [40] | |
MIP-1α | Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] |
IL-6 | Lung tissue (emphysema mice model) | CS + SB203580 | CS + SB203580/CS | Down-G | [55] |
AMs (COPD GOLD IV) | LPS + AZD7624 | COPD/healthy | Down-P | [144] | |
Circulating chemokine (COPD GOLD II) | GW856553 | GW856553/Placebo | Down-P | [149] | |
Guinea Pig BAL fluid | SB-239063 + LPS | SB 239063 + LPS/LPS | Down-P | [40] | |
Fibrinogen | Circulating chemokine (COPD GOLD II) | GW856553 | GW856553/Placebo | Down-P | [149] |
IL-8 | Circulating chemokine (COPD GOLD II) | GW856553 | GW856553/Placebo | Down-P | [149] |
HSP-27 | Circulating chemokine (COPD GOLD II) | SB-681323 | SB-681323/Placebo | Down-P | [44] |